Gritstone fails to convince
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
Venture-backed biotechs push into the clinic
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
